Tesamorelin 10 mg

A GHRH analogue with a trans-3-hexenoyl group that protects it from enzymatic degradation. It is the only compound in its class with a complete clinical programme aimed specifically at visceral fat.

CAS: 218949-48-5
Formula: C221H366N72O67S
Molecular weight: 5135.9 g/mol
Purity: ≥ 98% verified by HPLC
Presentation: Amber glass vial with lyophilized powder, vacuum sealed.
: Includes 3 ml BAC waterIn the same box, at no cost.

$210 USD

How it works

Stimulates endogenous, pulsatile growth hormone release from the pituitary.
Preserves physiological feedback, unlike exogenous GH administration.
The effect on visceral fat is mediated by the GH/IGF-1 axis.

Qué dice la evidencia

Significant reduction of visceral fat versus placebo at 26 weeks.

Route described in the studies

Route: Subcutaneous daily, preferably at night.
Preparation: Reconstitute with BAC WATER without shaking. Reconstituted stability is shorter than other compounds: 14 days.
Application site: Rotate between abdominal quadrants.

Documented effects

Arthralgia and peripheral oedema, dose-dependent
Paraesthesia in the hands
Raised IGF-1 requiring monitoring
Altered blood glucose in susceptible individuals

When it is not used

Active neoplasia
Hypopituitarism with axis dysfunction
Pregnancy and breastfeeding
Proliferative diabetic retinopathy

Storage

Lyophilised: 2 to 8 °C protected from light.
Reconstituted: 2 to 8 °C, within 14 days.
Shipping: Stable at ambient temperature in lyophilized form.

Preguntas frecuentes

Why is IGF-1 monitored?

It is the marker of cumulative exposure to the axis. Trials measure it at baseline and every three months to keep it within the age-appropriate physiological range.

Research use only

Este compuesto se vende únicamente para investigación de laboratorio y desarrollo analítico. No es un medicamento, no está aprobado por ninguna autoridad sanitaria, y no se vende para diagnosticar, tratar, curar ni prevenir ninguna enfermedad. No es apto para consumo humano ni animal.